Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Insmed Incorporated

INSM ✓ COMPLIANT ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Large Cap Analyst: BUY

Last Close

$127.28

▼ -1.18%

Market Cap $27.80B · Vol 596.80K

Key Metrics

P/E Ratio

N/A

FWD: 2,018.32

Market Cap

$27.80B

Large Cap

Div Yield

N/A

EPS Growth

+75.03%

YoY

RSI (14)

54.42

Momentum

Beta

0.81

vs Market

52W High

$212.59

40.13% below

52W Low

$90.41

40.78% above

Volume

596.80K

Avg 836.66K

P/B

50.46

Price-to-book

ROE

-249.28%

Return on equity

Free Float

99.46%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Insmed Incorporated (INSM) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does INSM pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.51%

-5.54%

+38.53%

-11.52%

YTD

-26.87%

-12.78%

+380.30%

+368.80%

Financials & Valuation

TTM · Annual

Total Revenue	$606.42M
Net Income	$-1,276,775,000.00
Revenue Growth (YoY)	+296.11%
Gross Margin	78.74%
Operating Margin	-164.04%
Net Profit Margin	-210.54%
ROE	-249.28%
ROA · ROIC	-59.29% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	2,018.32
PEG Ratio	N/A
P/S	57.12
P/B	50.46
P/FCF	N/A
EPS Growth	+75.03%
Outstanding Shares	218.38M

Technical Indicators

50-Day SMA	$117.02
200-Day SMA	$139.70
RSI (14)	54.42
Beta	0.81
52-Week High	$212.59
52-Week Low	$90.41

Volume Today	596.80K
Avg Daily Volume (30D)	836.66K
Relative Volume	0.71x
Volatility (10D)	34.60
Volatility (30D)	89.90
Free Float	99.46%

Analyst Consensus

BUY

Current Price $127.28

Mean Target $201.15

52W Low$90.41 52W High$212.59

Current

Target

$90.41 $212.59

Current Analyst target

+58.03% upside potential · 23 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG001S9SKW7

ISINUS4576693075

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateOct 28, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. -1.14% ARGX.BR argenx SE -1.09% ARGX argenx SE -1.82% 2269.HK WuXi Biologics (Cayman) Inc. -2.74% GMAB Genmab A/S -2.45%

Company Profile

Insmed Incorporated is a global biopharmaceutical company. It is advancing a diverse range of approved and mid- to late-stage investigational medicines and drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. Its pre-clinical research programs encompass a range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 and pre-clinical research programs. Its INS1148 is an investigational monoclonal antibody.